Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 337

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants

Open access
Pajtler, Kristian W., Mack, Stephen C., Ramaswamy, Vijay, Smith, Christian A., Witt, Hendrik, Smith, Amy, Hansford, Jordan R., von Hoff, Katja, Wright, Karen D., Hwang, Eugene, Frappaz, Didier, Kanemura, Yonehiro, Massimino, Maura, Faure-Conter, Cécile, Modena, Piergiorgio, Tabori, Uri, Warren, Katherine E., Holland, Eric C., Ichimura, Koichi, Giangaspero, Felice, Castel, David, von Deimling, Andreas, Kool, Marcel, Dirks, Peter B., Grundy, Richard G., Foreman, Nicholas K., Gajjar, Amar, Korshunov, Andrey, Finlay, Jonathan, Gilbertson, Richard J., Ellison, David W., Aldape, Kenneth D., Merchant, Thomas E., Bouffet, Eric, Pfister, Stefan M., Taylor, Michael D.·2017·Acta Neuropathologica

Abstract

Multiple independent genomic profiling efforts have recently identified clinically and molecularly distinct subgroups of ependymoma arising from all three anatomic compartments of the central nervous system (supratentorial brain, posterior fossa, and spinal cord). These advances motivated a consensus meeting to discuss: (1) the utility of current histologic grading criteria, (2) the integration of molecular-based stratification schemes in future clinical trials for patients with ependymoma and (3) current therapy in the context of molecular subgroups. Discussion at the meeting generated a series of consensus statements and recommendations from the attendees, which comment on the prognostic evaluation and treatment decisions of patients with intracranial ependymoma (WHO Grade II/III) based on the knowledge of its molecular subgroups. The major consensus among attendees was reached that treatment decisions for ependymoma (outside of clinical trials) should not be based on grading (II vs III). Supratentorial and posterior fossa ependymomas are distinct diseases, although the impact on therapy is still evolving. Molecular subgrouping should be part of all clinical trials henceforth.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00401-016-1643-0

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 337

Metadata

Authors
Pajtler, K. W., Mack, S. C., Ramaswamy, V., Smith, C. A., Witt, H., Smith, A., Hansford, J. R., von Hoff, K., Wright, K. D., Hwang, E., Frappaz, D., Kanemura, Y., Massimino, M., Faure-Conter, C., Modena, P., Tabori, U., Warren, K. E., Holland, E. C., Ichimura, K., Giangaspero, F., Castel, D., von Deimling, A., Kool, M., Dirks, P. B., Grundy, R. G., Foreman, N. K., Gajjar, A., Korshunov, A., Finlay, J., Gilbertson, R. J., Ellison, D. W., Aldape, K. D., Merchant, T. E., Bouffet, E., Pfister, S. M., & Taylor, M. D.
Venue
Acta Neuropathologica
Published
2016-11-17
Volume
133
Issue
1
Pages
5-12
ISSN
  • 0001-6322 (ISSN-L)
  • 1432-0533
OpenAlex
W2553451383
Cited by
337
References
28
FWCI
22.97
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. https://app.cochat.ai/papers/10.1007/s00401-016-1643-0
The paper
Pajtler, K. W., Mack, S. C., Ramaswamy, V., Smith, C. A., Witt, H., Smith, A., Hansford, J. R., von Hoff, K., Wright, K. D., Hwang, E., Frappaz, D., Kanemura, Y., Massimino, M., Faure-Conter, C., Modena, P., Tabori, U., Warren, K. E., Holland, E. C., Ichimura, K., . . . Taylor, M. D. (2017). The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathologica. https://doi.org/10.1007/s00401-016-1643-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.